MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression

Ziemssen, Tjalf; Vandercappellen, Jo; Mondragon, Valeria Jordan; Giovannoni, Gavin

doi:10.3390/jcm11154401

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the presented study is the first to analyze the thresholds for single-time-point SS-OCT measurements in evaluating MS clinical outcomes. The use of thresholds for single-time-point SS-OCT measurements may be a valuable complement to clinical decision support systems in a holistic approach to pwMS [ 43 ]. At the same time, we are aware of our study limitations.…”

Section: Discussionmentioning

confidence: 99%

Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients

Rzepiński¹,

Kucharczuk²,

Tkaczyńska³

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

This study aimed to determine whether peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell–inner plexiform layer (GCIPL) thickness thresholds for single-time-point swept-source optical coherence tomography (SS-OCT) measures can differentiate the clinical outcomes of treatment-naïve people with multiple sclerosis (pwMS). A total of 275 patients with the clinically isolated syndrome (n = 23), benign MS (n = 8), relapsing–remitting MS (n = 185), secondary progressive MS (n = 28), primary progressive MS (n = 31), and with no history of optic neuritis were included. The mean Expanded Disability Status Scale (EDSS) score was 3.0 ± 1.6. The cut-off values of pRNFL (87 µm and 88 µm) and GCIPL (70 µm) thicknesses have been adopted from previous studies using spectral-domain OCT. PwMS with pRNFL ≤87 µm and ≤88 µm had a longer disease duration, more advanced disability, and more frequently progressive MS variants compared to those with greater pRNFL thicknesses. In distinguishing pwMS with disability greater than or equal to the mean EDSS score (EDSS ≥ 3) from those with less severe disability, GCIPL thickness <70 µm had the highest sensitivity, while pRNFL thickness ≤87 µm had the greatest specificity. The optimal cut-off values differentiating patients with EDSS ≥ 3 from those with less severe disability was 63 µm for GCIPL thickness and 93.5 µm for pRNFL thickness. In conclusion, pRNFL and GCIPL thickness thresholds for single-time-point SS-OCT measurements may be helpful in differentiating the disability status of treatment-naïve pwMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients

Rzepiński¹,

Kucharczuk²,

Tkaczyńska³

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

show abstract

Building a monitoring matrix for the management of multiple sclerosis

Voigt

Inojosa

Wenk

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

Building digital patient pathways for the management and treatment of multiple sclerosis

Wenk,

Voigt,

Inojosa

et al. 2024

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Recent advances in the field of artificial intelligence (AI) could yield new insights into the potential causes of multiple sclerosis (MS) and factors influencing its course as the use of AI opens new possibilities regarding the interpretation and use of big data from not only a cross-sectional, but also a longitudinal perspective. For each patient with MS, there is a vast amount of multimodal data being accumulated over time. But for the application of AI and related technologies, these data need to be available in a machine-readable format and need to be collected in a standardized and structured manner. Through the use of mobile electronic devices and the internet it has also become possible to provide healthcare services from remote and collect information on a patient’s state of health outside of regular check-ups on site. Against this background, we argue that the concept of pathways in healthcare now could be applied to structure the collection of information across multiple devices and stakeholders in the virtual sphere, enabling us to exploit the full potential of AI technology by e.g., building digital twins. By going digital and using pathways, we can virtually link patients and their caregivers. Stakeholders then could rely on digital pathways for evidence-based guidance in the sequence of procedures and selection of therapy options based on advanced analytics supported by AI as well as for communication and education purposes. As far as we aware of, however, pathway modelling with respect to MS management and treatment has not been thoroughly investigated yet and still needs to be discussed. In this paper, we thus present our ideas for a modular-integrative framework for the development of digital patient pathways for MS treatment.

show abstract

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression

Cited by 4 publications

References 53 publications

Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients

Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-Naïve Multiple Sclerosis Patients

Building a monitoring matrix for the management of multiple sclerosis

Building digital patient pathways for the management and treatment of multiple sclerosis

Contact Info

Product

Resources

About